Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EBS $3.67 +90%
APVO 600k floater $1.25 + 29%
MARA RIOT CLSK everything crypto ASNS 3m floater going now .99 + 26%
EBS 2.98 NARCAN® — comprises contributions from NARCAN® Nasal Spray
Other Commercial Products - comprises contributions from Vaxchora® and Vivotif®, which we sold to Bavarian Nordic as part of our travel health business in May 2023
Anthrax MCM — comprises potential contributions from CYFENDUS®, previously known as AV7909, BioThrax®, Anthrasil® and Raxibacumab
Smallpox MCM — comprises potential contributions from ACAM2000®, VIGIV and TEMBEXA®
Other Products — comprises potential contributions from BAT®, RSDL® and Trobigard®
Bioservices — comprises service and lease revenues from the Bioservices business
KSCP + 10% .48 …human job killer AI
ALLR patience pays
CGC 10.41 -27% …in between zones might hold 10.89- 11.70 dip zone and 8.32- 9.55 one zone below
CTMX 5.85 + 239% next up …CTMX third zone up $6.29- 7.34.
CTMX 3.90 trying for next zone $3.89- $4.29 then $4.66-..
PLTN $9 should be a 100% percenter at least but 500m cap suggested so as high as 500% if really pushed…right now market cap 44m aprox..
SHENZHEN, China and NEW YORK, Oct. 10, 2023 /PRNewswire/ -- Big Tree Cloud International Group Limited ("Big Tree Cloud" or the "Company"), a company devoted to the development, production and sales of personal care products and other consumer goods in China, and Plutonian Acquisition Corp. ("Plutonian") (Nasdaq: PLTN), a publicly traded special purpose acquisition company, announced today that they have entered into a definitive merger agreement (the "Merger Agreement") that will result in Big Tree Cloud to be operated under a holding entity named Big Tree Cloud Holdings Limited, an exempted company incorporated in Cayman Islands ("PubCo") and to be traded on the Nasdaq Stock Market (the "Proposed Transaction"). The Proposed Transaction reflects an initial equity value of approximately US$500 million.
Founded in 2020, Big Tree Cloud has established itself as a dynamic and innovative consumer-oriented company committed to improving the lives of modern, health-conscious, and independent consumers through high-quality personal care products and consumer goods with a focus on a feminine hygiene products. At the core of its mission lies a dedication to the development, production and distribution of personal care items. Big Tree Cloud's consumer-to-manufacturer model has integrated its online and offline operations for an omni-channel sales model, and fostered an active community that contributes valuable feedback and product suggestions. This interaction with consumers is instrumental in shaping product development strategies and delivering premium products tailored to their personal care needs.
Big Tree Cloud's product portfolio places a strong emphasis on feminine hygiene products with its sterilized feminine pads and menstrual pants. The Company recognizes the increasing awareness among health-conscious consumers in China who seek quality, comfort, sanitary, and high-functionality in feminine hygiene products. Big Tree Cloud has positioned itself as a pioneer in meeting these demands through innovative sterilization technology, advanced absorbent core structures, and anti-leakage designs, all of which aimed at enhancing consumer satisfaction. The Company's comprehensive business strategy spans research and development, production, and marketing and enables it to offer a complete range of high-quality products to consumers.
Management Commentary
Mr. Wenquan Zhu, the founder and chairman of the board of Big Tree Cloud, stated that "this transaction marks a significant milestone in our journey towards providing better personal and hygienic care for families in China and around the world. We are proud of our achievements since our inception in 2020 and are thrilled about the growth opportunities that lie ahead. The proposed business combination with Plutonian Acquisition Corp. will enable us to accelerate our effort of accomplishing our mission of offering premium personal care products to consumers and expanding our product portfolio beyond feminine care. We are confident that this strategic move will enhance our market presence and further establish Big Tree Cloud as a trusted and innovative brand."
"We are excited to complete this business combination between Plutonian and Big Tree Cloud. The Plutonian team is honored to be part of this landmark occasion," said Wei Kwang Ng, CEO of Plutonian. "The entire exceptional management team at Big Tree Cloud continues to execute on their robust growth plans and strategy, with multiple compelling dynamics in the consumer goods industry, we firmly believe that Big Tree Cloud as a public company has the right model and technology to leverage its experience and platform to create shareholder value."
Transaction Overview
The Proposed Transaction values the combined company upon the closing of the Proposed Transaction ("Combined Company") at an implied pro forma pre-money enterprise value of approximately US$500,000,000, at a price of US$10.00 per share. Upon closing, the current shareholder of Big Tree Cloud will retain a majority of the outstanding shares of the Combined Business and Big Tree Cloud will designate a majority of the proposed directors for the Combined Company's board.
Proceeds from the Proposed Transaction are expected to be utilized for working capital and general corporate purposes.
The board of directors of both Big Tree Cloud and Plutonian have unanimously approved the Proposed Transaction, which is expected to be completed in the first half of 2024, subject to, among other things, approval by the shareholders of Plutonian and Big Tree Cloud, regulatory approvals and other customary closing conditions, including a registration statement on Form F-4 (the "Registration Statement") to be filed by the PubCo being declared effective by the SEC, and the listing application of the PubCo being approved by the Nasdaq Stock Market LLC.
Additional information about the Proposed Transaction, including a copy of the Merger Agreement, will be provided in a Current Report on Form 8-K to be filed by Plutonian with the SEC and available at https://www.sec.gov/.
DARE .35 nice to see it took out older .37 up to .39 looks like next churn should see .42 resistance hit
CGC $11.91 -17% 10.89- 11.70 should be new dip zone and 8.32- 9.55 one zone below
CTMX third zone up $6.29- 7.34. But first things first need some churn and hold support at 2.50- 2.86 zone
CTMX $3.16 +96% next zone $3.89- $4.29 then $4.66-$5.26
ROOT IMCC DPSI PLTN POAI ALCE HKIT NXU SISI IMTE HWH low floaters to watch
PALI hit $9.50s at 8.65 time to take quick profits although a keeper for a few shares 800k tiny float after rs
Time to scale out for sure
Boom
CTMX 3.22 + 100% time to scale out
IMCC needed to dip again reset
CGC $14.42 Pot stocks get ready to buy the dips CGC either $12 range or $10 for a ride to $17. TLRY MSOS ACB
IMCC 1.40 + 123%
Take your pick MSOX CGC ACB TLRY lol…April 30 (Reuters) - Shares of cannabis companies surged on Tuesday afternoon after the U.S. Department of Justice (DoJ) moved to reclassify marijuana as a less dangerous drug.
U.S.-listed shares of Cronos Group, Tilray Brands and Canopy Growth rose between 10.9% to 52%. ETF AdvisorShares Pure US Cannabis soared 21%.
Canada-listed Green Thumb Industries and Trulieve Cannabis were up 25% and 31% respectively.
The DoJ, which oversees the Drug Enforcement Administration, recommended that cannabis be classified as a so-called schedule three drug, with a moderate to low potential for physical and psychological dependence, instead of schedule one, which is reserved for drugs with a high potential for abuse, two sources confirmed to Reuters.
The proposal, which, if finalized, could potentially be the most significant shift in federal cannabis policy in 40 years, is being sent to the White House Office of Management and Budget for review and to finalize the rule-making process, the sources said.
The reclassification will not legalize marijuana outright for recreational use.
Shares of U.S.-listed marijuana companies had similarly soared in 2019 after Canada legalized recreational marijuana use, but the rally collapsed the following year as underwhelming revenue numbers failed to justify their sky-high valuations. (Reporting by Tanay Dhumal in Bengaluru; Editing by Tasim Zahid)
IMCC .88 + 55%
EFTR slow cooker $2.13 will check the red cat out
GRRR $6 + 11%
Unfortunately dilution so catch it now .54- .58 nice short play
AKLI .41 now was .46 hod scale out here also
AGBA $4s scale out 90%
AGBA 4.29
GRRR 5.67 + 5%
AGBA 3.65
AGBA 2.88 + 24%
AKLI .38!+’68% Under the terms of the amended agreement, Shionogi has canceled and forgiven a $5.0 million long-term debt obligation and agreed to make certain payments for SDT-001 (the Japanese, localized version of Akili’s AKL-T01 digital treatment, marketed as EndeavorRx® in the United States). Per the amendment, Akili will receive an upfront payment of $10.5 million in consideration for the elimination of future royalty payments and certain future milestone payments. Akili will also be eligible to receive up to a total of $4.5 million from Shionogi in consideration of Akili development and support services, with at least $1.5 million of such services fees payable up front, and up to a total of $3.0 million from Shionogi in potential regulatory milestone payments. SDT-001 is currently under marketing approval review in Japan as a potential digital treatment for children and adolescents with attention-deficit/hyperactivity disorder (“ADHD”).
In parallel, Akili’s board of directors has initiated a process that is currently ongoing to evaluate potential strategic alternatives to maximize shareholder valu
AKLI .38 + 61%
DARE .32 $22 million of non-dilutive capital at close provides significant capital to achieve objectives
Upon achieving a pre-specified return threshold, XOMA will make upside-sharing milestone payments to Dare´ representing 50% of the future payments otherwise payable to XOMA
Transaction allows Daré to focus on advancing Phase 3 first-in-category investigational products Ovaprene®, a potential first FDA-approved hormone-free intravaginal monthly contraceptive, and Sildenafil Cream, 3.6%, a potential first FDA-approved treatment for female sexual arousal disorder through key catalysts
Previously announced royalty financing remains outstanding, bringing royalty-based capital committed to $34 million
SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has closed a royalty monetization transaction with XOMA (US) LLC. Daré received $22 million in gross proceeds at close and, following a pre-specified total return to XOMA, XOMA will make upside-sharing milestone payments to Daré equal to 50% of all remaining cash flows sold to XOMA under the transaction.
“This monetization of future net royalty and net milestone payments based on net sales of XACIATO™ (clindamycin phosphate) vaginal gel 2% under our license agreement with Organon, along with a low single digit minority interest in net payments related to future revenue from our Phase 3 candidates, Ovaprene and Sildenafil Cream, accelerates potential cash flows from the future commercial success of XACIATO and such product candidates, providing us with non-dilutive capital at an opportune time to drive shareholder value through the continued advancement of Ovaprene and Sildenafil Cream, both of which are first-in-category and represent large market opportunities,” said Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience.
“Importantly, this transaction ensures that Daré and our shareholders have the opportunity to participate meaningfully in XACIATO economics as commercialization progresses. The structure of these agreements also underscores the significant potential of Ovaprene and Sildenafil Cream, with Daré retaining the significant majority of future economics and the ability to achieve attractive margins through retained net sales and all commercial milestones. This transaction exemplifies our commitment to being creative, collaborative and opportunistic in seeking capital at an attractive cost to advance our potential first-in-category Phase 3 candidates to deliver value for all Daré stakeholders.”
The transaction involves the sale of (a) the remaining royalties and potential milestones based on net sales of XACIATO payable to Daré under its global license agreement with Organon after deducting (i) all amounts due on such royalties and milestone payments to third-party licensors, and (ii) all payments owed by Daré under its existing royalty interest financing agreement with United in Endeavour, LLC, (b) 25% of the potential $20 million payment due to Daré under its license agreement with Bayer relating to Ovaprene, in the event Bayer, in its sole discretion, elects to make the payment1, and (c) a 4% synthetic royalty on net sales of Ovaprene and a 2% synthetic royalty on net sales of Sildenafil Cream, subject to an automatic decrease to 2.5% and 1.25%, respectively, as described below. Once XOMA achieves a pre-specified total return on its investment, XOMA will pay to Daré 50% of each successive $22 million that XOMA receives under the transaction agreements, and, once XOMA achieves another pre-specified total return on its investment, the synthetic royalty rates on net sales of Ovaprene and Sildenafil Cream will automatically decrease to 2.5% and 1.25%, respectively, which, after taking into account the $11 million payments to Daré after XOMA achieves the initial pre-specified total return, results in a lower effective royalty rate.
TD Cowen, a division of TD Securities, acted as exclusive financial advisor to Daré Bioscience on the transaction. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. served as Daré’s legal advisor while XOMA was advised by Gibson, Dunn & Crutcher LLP.
Additional information regarding the transaction is available in Daré’s Current Report on Form 8-K filed with the Securities and Exchange Commission today.
1 - Daré retains 75% of the potential $20 million payment and has no downstream obligations with respect to such payment.
Like there style lol.. 4,968,945 shares of common stock at a purchase price of $1.61 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under Nasdaq rules. The series A warrants and short-term series B warrants will have an exercise price of $1.36 per share and will be exercisable immediately upon issuance. The series A warrants will expire five and one-half years from the date of issuance and the short-term series B warrants will expire eighteen months from the date of issuance. The private placement is expected to close on or about May 2, 2024, subject to the satisfaction of customary closing conditions.
AWIN since 4.63 wasn’t bottom now we have a 3.18- 3.51 level then 4.21- 4.63 to consider
CYCC 2.25 for those still holding 2.37 -2.63 next zone of interest if breaks out of 2.32.. 1m floater